SOLICITATION NOTICE
B -- Measurement of Serum C-Reactive Protein adn Serum Amyloid A with the HEAL study
- Notice Date
- 8/17/2005
- Notice Type
- Solicitation Notice
- NAICS
- 622110
— General Medical and Surgical Hospitals
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-50137-NG
- Response Due
- 9/1/2005
- Archive Date
- 9/16/2005
- Description
- In accordance with Simplified Acquisition procedures, The National Cancer Institute (NCI), Applied Research Program (ARP), plans to procure on a sole source basis, for analysis of Measurement of Serum C-reactive protein and Serum-Amyloid A for Health, Eating, Activity, Lifestyle (HEAL) Study of Breast Cancer Prognosis with the University of Washington, 1959 NE Pacific Street, Seattle, Washington 98105. The North American Industry Classification System code is 622110 and the business size standard is $29M. The supplies and services herein are being procured in accordance with the simplified acquisition procedures stated in FAR Part 13. Acute-phase proteins, such as C-reactive protein (CRP) and serum-amyloid A (SAA) are non-specific markers of low-grade inflammation and are elevated among breast cancer patients. These proteins are also elevated among women who have an increased risk of breast cancer or a worse prognosis, specifically older or overweight, obsess women. The purpose of this project is to assay stored serum for CRP and SAA in the laboratory of Dr. Mark Wener at the University of Washington. Assays shall be performed on serum that is to be drawn at the twenty-four (24) month interview from eligible women. These women are currently part of the HEAL study where prior data and future data has been and will continue to be collected and processed. Dr. Wener is a collaborator with the HEAL study investigators and is a leading expert in this technique. The laboratory of Dr. Mark Wener at the University of Washington is the only source known to the NCI that can provide assay services and has extensive experience in C-reactive protein and serum amyloid for clinical research and studies. Changing variables at this time will be detrimental to the current study in progress. This is not a solicitation for competitive quotations. However, if any interested party believes it can provide the above service, and has the support of the above listed partners, it may submit a statement of capabilities. The statement of capabilities and any other information must be in writing and must contain sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 1:00 PM EDT on September 1, 2005. All questions must be in writing and can be faxed to (301) 402-4513 or sent via electronic mail to holdcram@exchange.nih.gov. It is the vendors? responsibility to call 301-402-4509 to insure all questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA).
- Record
- SN00872471-W 20050819/050817211753 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |